Neisa Torres Reyes, MD
Internal Medicine · Bayamon, PRNPI 1629016829
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,184 of the $7,997 with a category attached, or 77.3%. 26 manufacturers reported payments, led by Merck at 26.0% of the total. Among internal medicine clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- AstraZeneca$1K
- GSK$1K
- Boehringer Ingelheim$815
- Viatris Specialty LLC$282
- Mylan Specialty L.p.$248
- plus $2K from 20 others
What the payments were for
- Consulting fees$1,50019%
- Food & beverage$6,18477%
- Education$3134%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 19 | $2,078 |
| AstraZeneca | 42 | $1,302 |
| GSK | 48 | $1,043 |
| Boehringer Ingelheim | 33 | $815 |
| Viatris Specialty LLC | 10 | $282 |
| Mylan Specialty L.p. | 12 | $248 |
| Sanofi | 10 | $235 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $231 |
| Amgen | 11 | $226 |
| Johnson & Johnson | 10 | $215 |
| Mallinckrodt Hospital Products Inc. | 2 | $184 |
| Gilead | 9 | $164 |
| Bayer | 7 | $160 |
| Grifols USA, LLC | 7 | $129 |
| Terumo Medical Corporation | 1 | $117 |
| Actelion Pharmaceuticals US, Inc. | 2 | $113 |
| Genentech USA, Inc. | 1 | $67 |
| Abbott | 3 | $62 |
| Jazz Pharmaceuticals Inc. | 2 | $60 |
| Pfizer | 2 | $59 |
| Shire North American Group Inc | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Mylan LLC | 2 | $41 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| PBG Puerto Rico LLC | 1 | $25 |
| United Therapeutics Corporation | 3 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,997 in reported general payments places this provider in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AdempasRiociguat | 138 | $1,920,077 |
| Breo ElliptaFluticasone/Vilanterol | 530 | $225,487 |
| OfevNintedanib Esylate | 17 | $223,507 |
| Atrovent HfaIpratropium Bromide | 257 | $122,390 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 172 | $114,138 |
| Spiriva RespimatTiotropium Bromide | 200 | $110,429 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 138 | $67,810 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,190 | $51,141 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 181 | $45,260 |
| Fluticasone Propionate HfaFluticasone Propionate | 144 | $37,111 |
| SymbicortBudesonide/Formoterol Fumarate | 139 | $31,977 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $19,299 |
| Fluticasone Propionate | 706 | $12,700 |
| Wixela InhubFluticasone Propion/Salmeterol | 72 | $8,978 |
| Montelukast Sodium | 835 | $8,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerAdempas | $160 | $1,920,077138 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $815 | $401,746355 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $1,043 | $339,625702 claims |
| AstraZenecaSymbicort, Breztri Aerosphere | $1,302 | $51,276169 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick | $32 | $8,24744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,043 internal medicine providers in Puerto Rico.
Other internal medicine in Bayamon
- Sixto MedinaBayamon$15K
- Graciela Latalladi OrtegaBayamon$11K
- Pedro Roman EyxarchBayamon$9K
- Luis FortiBayamon$8K
- Carlos AcostaBayamon$7K
- Jose Aviles MunozBayamon$6K
- Steven CruzBayamon$6K
- Lionel Velez MontijoBayamon$6K
- Wanda Beltran VirellaBayamon$5K
- Nelson VallejoLas Piedras$621K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.